America is in an opioid epidemic. On an average day, 91 Americans will die from an opioid-related overdose. That’s according to the CDC, which also reports that the number of prescription opioids sold in the U.S. has nearly quadrupled since 1999 despite no overall change in the amount of pain reported.
Cannabis is now legal medically or recreationally in 28 states in the U.S., and companies such as India Globalization Capital, Inc. (NYSE MKT: IGC) are developing revolutionary cannabinoid-based combination pharmaceutical therapies.
The fastest-growing industry with the most consistent growth rate in North America is legal marijuana. A recent Forbes article says that the market could grow 700% by 2020.
Its drug development pipeline consists of treatments for seizures, neuropathic pain, and eating disorders, but one gaining attention is an experimental cannabis-based drug for Alzheimer’s disease, IGC-AD1.
Not satisfied with a 100,000+ user base, a recognizable 18-year-old brand, and a target market in excess of two billion Chinese speaking people, ChineseInvestors.com recently executed a first-to-market milestone by creating the world’s only Chinese language, cannabinoid-based, therapeutic health products online store, http://www.ChineseCBDoil.com.
In addition to its San Gabriel store, the company also owns and operates an online store based in the free trade zone of Shanghai, China.
India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical therapies to fight a variety of ailments.
The backbone of medical advancement is biotechnology, an industry wrought with the incredible potential of novel drug R&D, but vulnerable to the risk of stringent regulatory approval processes. Within this volatile market, however, is the cannabis-biotech sub-sector – a market flourishing with opportunity, innovation, and deep roots of medical possibilities.
Many patients rely on Chinese herbs for temporary control. However, ChineseInvestors.com’s (OTCQB: CIIX) current development plan includes making cannabidiol (CBD) products available online for people with epilepsy and Alzheimer’s disease.
The company operates the first online Chinese language CBD health product store. Now, two billion Chinese can order their medicine online and have it delivered to their homes.
Alzheimer’s disease is a devastating brain disorder that now affects about 5.3 million Americans, accounting for one in nine people over the age of 65, according to the Alzheimer’s Association.
Combination therapies that use cannabis-based pain reduction methods without the negative side effects of opioids are looking to be a positive growth opportunity among specialty pharmaceuticals, particularly for postoperative and chronic pain relief.
Changes in public opinion regarding cannabis have greatly fueled the fire blazing under the red-hot state-legalized marijuana market.
NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB: CIIX), a client of NNW recognizing unprecedented opportunities in the U.S. cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.
China’s growing economy has proven to be beneficial to many across the country. Some of these benefits include higher living standards, better health and nutrition, and longer life expectancy.
